Pharmacy operations update

Medpal AI PLC

05 February 2026

 

5 February 2026

MedPal AI plc

("MedPal AI" or the "Company")

Pharmacy - Operational Update

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce the continued strong performance of automated pharmacy operations at its wholly-owned subsidiary, MedPal Limited. MedPal AI combines its user-friendly mobile app, AI-driven diagnosis and triage with human-in-the-loop clinical oversight and prescribing services, with high-tech robotic pharmacy dispensing.

January 2026 Dispensing Performance

The Company is pleased to report that its pharmacy operations dispensed 36,951 items during January 2026, representing growth of 10.5% compared to 33,433 items dispensed in December 2025. Based on an average item value of £9.70, this volume of activity continues to support monthly pharmacy revenue in excess of £350,000 per month.

This sustained growth in dispensing volumes further demonstrates the effectiveness of the Company's advanced AI triage system and state-of-the-art robotic dispensing infrastructure, together with increasing patient demand for both NHS and private prescription services, including through the MedPal.clinic weight-loss platform.

Jason Drummond, CEO of MedPal AI, commented:

"January has delivered another excellent month of growth, with over 10% more prescriptions dispensed than in December. This performance reflects the scalability and resilience of our automated pharmacy model and reinforces our confidence in the ongoing expansion of our digital health offering."

The Board continues to closely monitor trading and will provide further updates as appropriate.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

END